Straits Times Index
3,168.92 -18.74 (-0.59%) Nikkei
37,161.96 -917.74 (-2.41%) Hang Seng
16,184.02 -201.85 (-1.23%) FTSE 100
7,877.05 +29.06 (+0.37%) Bitcoin USD
62,611.94 +707.62 (+1.14%) CMC Crypto 200
1,285.71 +400.17 (+43.91%)
Roche Holding AG (RO.SW)
| Previous close | 237.40 |
| Open | 237.60 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 235.40 - 238.40 |
| 52-week range | 229.40 - 318.00 |
| Volume | |
| Avg. volume | 34,455 |
| Market cap | 177.186B |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | 16.56 |
| EPS (TTM) | 14.30 |
| Earnings date | N/A |
| Forward dividend & yield | 9.60 (4.04%) |
| Ex-dividend date | 14 Mar 2024 |
| 1y target est | 263.00 |
Business WireFDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
SOUTH SAN FRANCISCO, Calif., April 18, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Alecensa® (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test. Alecensa is now the first and only ALK inhibitor approved for people wi
Business WireGenentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
SOUTH SAN FRANCISCO, Calif., April 17, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from the Phase III OCARINA II study (S31.006) of Ocrevus® (ocrelizumab), an investigational twice-yearly, 10-minute subcutaneous (SC) injection. Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential benefits of this investigatio
GlobeNewswireRoche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeksThe twice-yearly, 10-minute SC injection has the potential to expand the usage of OCREVUS to treatment centres without IV infrastructure or with IV capacity limitationsU.S. FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. ap
